Dr. Volker Heinemann on the Addition of SIRT to Chemotherapy for mCRC
Volker Heinemann, MD, PhD, director of the Comprehensive Cancer Center at Ludwig Maximilian University of Munich, discusses how depth of response, which is highly correlated with overall survival, was improved for patients with metastatic colorectal cancer who added selective internal radiation therapy (SIRT) to chemotherapy.
Volker Heinemann, MD, PhD, director of the Comprehensive Cancer Center at Ludwig Maximilian University of Munich, discusses how depth of response, which is highly correlated with overall survival, was improved for patients with metastatic colorectal cancer who added selective internal radiation therapy (SIRT) to chemotherapy.
Patients with high tumor burden in the liver also showed a positive response to the addition of SIRT, with a 20% improvement in depth of response and and a 14-month improvement in progression-free survival (PFS). Heinemann said that since the liver is essential, these results are clinically relevant.
